Form 4: Jayagopal Ashwath reports disposition transactions in IRD

Rhea-AI Filing Summary

Jayagopal Ashwath reported disposition transactions in a Form 4 filing for IRD. The filing lists transactions totaling 5,313 shares at a weighted average price of $3.39 per share. Following the reported transactions, holdings were 520,494 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jayagopal Ashwath

Role Chief Scientific & Dev. Ofc.

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	5,313	$3.39	$18K

Holdings After Transaction: Common Stock — 520,494 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jayagopal Ashwath

(Last) (First) (Middle)

C/O OPUS GENETICS, INC.

8 DAVIS DRIVE, SUITE 220

(Street)

DURHAM NC 27713

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Opus Genetics, Inc. [ IRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific & Dev. Ofc.

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/12/2026		F(1)		5,313	D	$3.39	520,494	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Issuer withheld the shares reported on this line to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. Not an open market sale of securities.

	/s/ Amy Rabourn, by Power of Attorney	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Opus Genetics (IRD) report for Jayagopal Ashwath?

Opus Genetics reported a tax-withholding disposition by Chief Scientific & Dev. Officer Jayagopal Ashwath. On 02/12/2026, 5,313 common shares at $3.39 were withheld to cover taxes from a restricted stock unit vesting, rather than sold on the open market.

Was the Opus Genetics (IRD) Form 4 transaction an open market sale?

The Form 4 transaction was not an open market sale. The issuer withheld 5,313 common shares solely to satisfy tax withholding obligations arising from a restricted stock unit vesting and settlement event, according to the explanatory footnote in the filing.

How many Opus Genetics (IRD) shares does Jayagopal Ashwath own after the Form 4 event?

After the reported transaction, Jayagopal Ashwath beneficially owned 520,494 common shares of Opus Genetics directly. This balance reflects the withholding of 5,313 shares used to cover tax obligations tied to a restricted stock unit vesting on 02/12/2026.

What does transaction code F mean in the Opus Genetics (IRD) Form 4?

In this Form 4, code F denotes a tax-withholding disposition. It indicates that 5,313 Opus Genetics common shares were withheld at $3.39 per share to pay tax liabilities from a restricted stock unit vesting, instead of being sold in the open market.

What role does Jayagopal Ashwath hold at Opus Genetics (IRD)?

Jayagopal Ashwath serves as Chief Scientific & Development Officer of Opus Genetics, Inc. The Form 4 identifies him as an officer, not a director or 10% owner, and reports his direct ownership of 520,494 common shares after the tax-withholding transaction.

On what date did the reported Opus Genetics (IRD) insider transaction occur?

The insider transaction occurred on February 12, 2026. On that date, Opus Genetics withheld 5,313 common shares from Chief Scientific & Dev. Officer Jayagopal Ashwath at $3.39 per share to satisfy tax withholding obligations from a restricted stock unit vesting.